Review
Gene Therapy (2008) 15, 877–884; doi:10.1038/gt.2008.72; published online 17 April 2008
Gene therapy progress and prospects cancer: oncolytic viruses
- 1Department of Clinical Research, Jennerex Biotherapeutics Inc., San Francisco, CA, USA
- 2Department of Pharmacology, School of Medicine, University of Oxford, Oxford, UK
Correspondence: Dr D Kirn, Jennerex Biotherapeutics Inc., One Market Street, Spear Tower, Suite 2260, San Francisco, CA 94105, USA. E-mail: dkirn@jennerex.com
Received 14 January 2008; Revised 7 March 2008; Accepted 10 March 2008; Published online 17 April 2008.
Abstract
The past 2 years have seen several major advances in oncolytic virotherapy. Studies on the interaction between viruses, immune responses and tumor microenvironment have provided important insight, while clinical trials have shown promise. This review summarizes key findings in this field over the past 2 years, and provides directions for future success.
Keywords:
cancer, oncolytic, virus, replication
Abbreviations:
CAR, coxsackievirus-adenovirus receptor; CIK, cytokine-induced killer; CTL, cytotoxic T lymphocyte; EGFR, epidermal growth factor receptor; HDAC, histone deacetylase; HSV, herpes simplex virus; IFN, interferon; MMP, matrix metalloproteinase; MOA, mechanism-of-action; PBMC, peripheral blood mononuclear cells; TK, thymidine kinase; Treg, regulatory T cells; TSA, trichostatin A; VSV, vesicular stomatitis virus
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Nature Clinical Practice Oncology Review (01 Feb 2007)
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Nature Clinical Practice Oncology Review (01 Feb 2007)
Nature Medicine Review (01 Jul 2001)
RESEARCH
Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses
Molecular Therapy Original Article
Nature Medicine Article (01 Jan 2008)
